2541 related articles for article (PubMed ID: 6767404)
41. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
42. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.
Rosenfeld WE; Doose DR; Walker SA; Nayak RK
Epilepsia; 1997 Mar; 38(3):317-23. PubMed ID: 9070594
[TBL] [Abstract][Full Text] [Related]
43. Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives.
Kojima T; Lindheim SR; Duffy DM; Vijod MA; Stanczyk FZ; Lobo RA
Am J Obstet Gynecol; 1993 Dec; 169(6):1540-4. PubMed ID: 8267059
[TBL] [Abstract][Full Text] [Related]
44. The effect of oral contraceptives on mononuclear cell cholesteryl ester hydrolase activity.
Hagemenas FC; Yatsu FM; Manaugh LC
Lipids; 1980 Jan; 15(1):39-44. PubMed ID: 7360009
[TBL] [Abstract][Full Text] [Related]
45. Effect of oral contraceptives on plasma androgenic steroids and their precursors.
Fern M; Rose DP; Fern EB
Obstet Gynecol; 1978 May; 51(5):541-4. PubMed ID: 148599
[TBL] [Abstract][Full Text] [Related]
46. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
[TBL] [Abstract][Full Text] [Related]
47. Norgestimate: a clinical overview of a new progestin.
Bringer J
Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1969-77. PubMed ID: 1605287
[TBL] [Abstract][Full Text] [Related]
48. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol.
Winkler UH; Schindler AE; Endrikat J; Düsterberg B
Contraception; 1996 Feb; 53(2):75-84. PubMed ID: 8838483
[TBL] [Abstract][Full Text] [Related]
49. A radioimmunoassay for norethindrone (NET): measurement of serum NET concentrations following ingestion of NET-containing oral contraceptive steroids.
Stanczyk FZ; Brenner PF; Mishell DR; Ortiz A; Gentzschein EK; Goebelsmann U
Contraception; 1978 Dec; 18(6):615-33. PubMed ID: 750188
[TBL] [Abstract][Full Text] [Related]
50. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
[TBL] [Abstract][Full Text] [Related]
51. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
Letterie GS
Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
[TBL] [Abstract][Full Text] [Related]
52. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel.
Elkik F; Basdevant A; Jackanicz TM; Guy-Grand B; Mercier-Bodard C; Conard J; Bardin CW; Corvol P
J Clin Endocrinol Metab; 1986 Jul; 63(1):29-35. PubMed ID: 3086360
[TBL] [Abstract][Full Text] [Related]
53. A quantitative study of the pregnancy zone protein in sera of woman taking oral contraceptives.
Damber MG; von Schoultz B; Solheim F; Stigbrand T
Am J Obstet Gynecol; 1976 Feb; 124(3):289-92. PubMed ID: 55075
[TBL] [Abstract][Full Text] [Related]
54. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
Rossmanith WG; Steffens D; Schramm G
Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
[TBL] [Abstract][Full Text] [Related]
55. A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings. I-Use effectiveness. An international comparative trial.
Sivin I; Mishell DR; Victor A; Diaz S; Alvarez-Sanchez F; Nielsen NC; Akinla O; Pyorala T; Coutinho E; Faundes A; Roy S; Brenner PF; Ahren T; Pavez M; Brache V; Giwa-Osagie OF; Fasan MO; Zausner-Guelman B; Darze E; Gama daSilva JC; Diaz J; Jackanicz TM; Stern J; Nash HA
Contraception; 1981 Oct; 24(4):341-58. PubMed ID: 6459208
[TBL] [Abstract][Full Text] [Related]
56. Oral contraceptives and antithrombin III: variations by dosage and ABO blood group.
Burkman RT; Bell WR; Zacur HA; Kimball AW
Am J Obstet Gynecol; 1991 Jun; 164(6 Pt 1):1453-8; discussion 1458-60. PubMed ID: 2048592
[TBL] [Abstract][Full Text] [Related]
57. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives.
Oyelola OO
Contraception; 1993 May; 47(5):445-54. PubMed ID: 8513671
[TBL] [Abstract][Full Text] [Related]
58. A norgestimate-containing oral contraceptive: review of clinical studies.
Kafrissen ME
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
[TBL] [Abstract][Full Text] [Related]
59. Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring. II. Serum lipoproteins and apolipoproteins.
Ahrén T; Lithell H; Victor A; Vessby B; Johansson ED
Contraception; 1981 Oct; 24(4):451-68. PubMed ID: 6797786
[TBL] [Abstract][Full Text] [Related]
60. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
Endrikat J; Müller U; Düsterberg B
Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
